1,077 results

#137139-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP (#137139). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of ChR2(E123T/T159C)-EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 19, 2021

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#114470-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 15, 2021

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#140137-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-iFlpV (#140137). In addition to the viral particles, you will also receive purified pAAV-EF1a-iFlpV plasmid DNA. EF1a-driven, light-inducible iFlpV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Oct. 28, 2021

Academic Institutions and Nonprofits only

#104496-PHPeB

Ready-to-use AAV PHP.eB particles produced from pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE (#104496). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE plasmid DNA. CAG-driven, Cre-dependent jGCaMP7f calcium sensor. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#121538-AAV2

Ready-to-use AAV2 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Sept. 25, 2019

Academic Institutions and Nonprofits only

#104493-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP7b-WPRE (#104493). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7b-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7b expression. jGCaMP7b expression exhibits the brightest resting fluorescence and can be used for imaging of small neuronal processes (dendrites and axons). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Nov. 14, 2019

Academic Institutions and Nonprofits only

#172908-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE (#172908). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE plasmid DNA. Syn-driven, Cre-dependent Ace2N-4AA-mNeon-ST A122D expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Abdelfattah et al Neuron. 2023 Mar 28:S0896-6273(23)00205-

Feb. 14, 2022

Academic Institutions and Nonprofits only